Clinical Trials Logo

Flu clinical trials

View clinical trials related to Flu.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06057727 Active, not recruiting - Behavior, Health Clinical Trials

Behavioral Economics to Improve Flu Vaccination Using EHR Nudges

BE IMMUNE
Start date: September 25, 2023
Phase: N/A
Study type: Interventional

This study will be a multisite, cluster randomized, pragmatic trial to evaluate the effectiveness of personalized nudges to clinicians and patients, relative to a control, to increase flu vaccination rates among older adults in accordance with CDC guidelines. This will include clinician and patient level nudge interventions, with an additional, intensified nudge intervention for patients identified as high risk for not receiving a flu vaccine. Among the intervention clinics, patients will receive pre-visit text message reminders about the flu vaccine, and clinicians will receive a default pended order in the visit encounter in the EHR, along with monthly peer comparison feedback about their flu vaccine completion rate. Patients identified as high risk for noncompletion will be individually randomized to receive an additional bidirectional text message nudge or the standard text messaging.

NCT ID: NCT02188810 Active, not recruiting - Flu Clinical Trials

Safety and Reactogenicity of a PAL Combined With Seasonal Flu Vaccine in Healthy Adults

Start date: April 2014
Phase: Phase 1
Study type: Interventional

This is a phase 1, research study is looking at the safety and acceptability of a new vaccine adjuvant (immune booster) called PAL when combined with the seasonal flu vaccine (Fluviral) to test the safety and effectiveness of new vaccines and medications on healthy volunteers. The study will enroll approximately 48 healthy adult participants, and occur over 3 years. In the first six months/180 days of the study participants will have visits to the study site during which safety and immunogenicity outcomes will be measured. From Day 181 to Year 3, participants will be contacted by telephone or email to collect information on any adverse events.